Scarica l'app Stockscreener
43.42
2.70%
1.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$42.28
Aprire:
$42.49
Volume 24 ore:
685.81K
Relative Volume:
0.83
Capitalizzazione di mercato:
$883.23M
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-29.74
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
-2.41%
1M Prestazione:
-20.84%
6M Prestazione:
+70.07%
1 anno Prestazione:
+4,418%
Intervallo 1D:
$41.51
$44.27
Intervallo di 1 settimana:
$41.32
$44.40
Portata 52W:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Confronta NKTR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
43.42 | 860.04M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
Top 10 skin disorder stories of 2025 - Healio
Simplify Asset Management Inc. Buys 35,176 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Wrap: Why Nektar Therapeutics stock could rally in 2025Earnings Growth Summary & Risk Adjusted Buy/Sell Alerts - moha.gov.vn
Dermatology Times 2025 Year in Review: Atopic Dermatitis - Dermatology Times
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Brain Implants for Mental Health and Chinese Competition Expected to Shape BCI Advancements by 2026 - geneonline.com
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25% - simplywall.st
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Nektar Therapeutics (NKTR) CEO reports RSU and stock option grants - Stock Titan
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Earnings Miss Alerts & Maximize ROI With Proven Growth Stocks - Bollywood Helpline
Published on: 2025-12-23 18:23:01 - moha.gov.vn
Nektar Therapeutics announces phase 2b trial results - MSN
Atopic Dermatitis in 2025: Year in Review - HCPLive
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data - Benzinga
Transformative Advances This Year and Beyond - Dermatology Times
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) - Insider Monkey
Is Nektar Therapeutics (ITH0) stock ideal for retirement investors2025 Trading Volume Trends & Accurate Buy Signal Alerts - ulpravda.ru
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions - Seeking Alpha
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows - Yahoo Finance
Machine Learning Tool vConTACT3 Developed to Enhance Global Virus Classification - geneonline.com
Is Nektar Therapeutics stock resilient to inflationMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Why analysts remain bullish on Nektar Therapeutics stockMarket Rally & Reliable Price Breakout Signals - DonanımHaber
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Assessing Nektar Therapeutics (NKTR) Valuation After a Volatile Year and Recent Share Price Pullback - simplywall.st
Nektar Therapeutics Q3 2025 Earnings Preview - MSN
Oppenheimer maintains Outperform rating on Q32 Bio stock at $20 target - Investing.com
Nektar Therapeutics announces top-line results from alopecia areata study - PMLiVE
Nektar Therapeutics Price Target Raised to $118.00/Share From $100.00 by BTIG - 富途牛牛
Nektar Therapeutics Is Maintained at Buy by BTIG - 富途牛牛
Nektar Therapeutics stock price target raised to $135 at H.C. Wainwright on alopecia data - Investing.com Nigeria
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg (NASDAQ:NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 6.5%Should You Sell? - MarketBeat
Rezpegaldesleukin Demonstrates Proof of Concept in Phase 2b Trial for Severe Alopecia Areata - Patient Care Online
Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $121 - news.futunn.com
Nektar Therapeutics to Advance Rezpeg into Phase III Trials for Alopecia Areata Despite Phase II Endpoint Miss - geneonline.com
Nektar Therapeutics Earnings Notes - Trefis
BTIG Research Issues Positive Forecast for Nektar Therapeutics (NASDAQ:NKTR) Stock Price - MarketBeat
REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata - HCPLive
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg - BioSpace
Nektar reports positive Ph IIb results in alopecia areata - The Pharma Letter
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment - TipRanks
BTIG Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nektar Therapeutics Azioni (NKTR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | Chief Legal Officer |
Nov 25 '25 |
Sale |
54.28 |
630 |
34,196 |
21,585 |
| ROBIN HOWARD W | President & CEO |
Nov 25 '25 |
Sale |
54.28 |
2,207 |
119,796 |
54,245 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):